Evidence map›Paper›PMID 40309232›Full record

ArticleWorld journal of gastroenterology2025

Multi-omics reveals the associations among the fecal metabolome, intestinal bacteria, and serum indicators in patients with hepatocellular carcinoma.

Jing Feng, Jun-Ping Wang, Jian-Ran Hu, Ping Li, Pin Lv, Hu-Cheng He, Xiao-Wei Cheng, Zheng Cao, Jia-Jing Han, Qiang Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jing FengDepartment of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Jun-Ping WangDepartment of Gastroenterology, Shanxi Provincial People's Hospital, Affiliated to Shanxi Medical University, Taiyuan 030012, Shanxi Province, China.
Jian-Ran HuDepartment of Biological Science and Technology, Jinzhong University, Jinzhong 030619, Shanxi Province, China.
Ping LiDepartment of Biological Science and Technology, Jinzhong University, Jinzhong 030619, Shanxi Province, China.
Pin LvDepartment of Gastroenterology, Shanxi Provincial People's Hospital, Affiliated to Shanxi Medical University, Taiyuan 030012, Shanxi Province, China.
Hu-Cheng HeDepartment of Gastroenterology, Shanxi Provincial People's Hospital, Affiliated to Shanxi Medical University, Taiyuan 030012, Shanxi Province, China.
Xiao-Wei ChengDepartment of Interventional Therapy, Shanxi Provincial People's Hospital, Affiliated to Shanxi Medical University, Taiyuan 030012, Shanxi Province, China.
Zheng CaoDepartment of Gastroenterology, Shanxi Provincial People's Hospital, Affiliated to Shanxi Medical University, Taiyuan 030012, Shanxi Province, China.
Jia-Jing HanDepartment of Gastroenterology, Shanxi Provincial People's Hospital, Affiliated to Shanxi Medical University, Taiyuan 030012, Shanxi Province, China.
Qiang WangDepartment of Infectious Diseases and Hepatology, Shanxi Provincial People's Hospital, Affiliated to Shanxi Medical University, Taiyuan 030012, Shanxi Province, China.
Qian SuDepartment of Infectious Diseases and Hepatology, Shanxi Provincial People's Hospital, Affiliated to Shanxi Medical University, Taiyuan 030012, Shanxi Province, China.
Li-Xin LiuDepartment of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China. lixinliu6@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is a key contributor to cancer-related deaths globally. However, HCC diagnosis solely based on blood biochemical markers lacks both sensitivity and specificity.

aimTo investigate alterations of the fecal metabolome and intestinal bacteria and reveal the correlations among differential metabolites, distinct bacteria, and serum indicators.

methodsTo uncover potentially effective therapeutic targets for HCC, we utilized non-targeted liquid chromatography-mass spectrometry and high-throughput DNA sequencing targeting the 16S rRNA gene. This comprehensive approach allowed us to investigate the metabolome and microbial community structure of feces samples obtained from patients with HCC. Furthermore, we conducted an analysis to assess the interplay between the fecal metabolome and intestinal bacterial population.

resultsIn comparison to healthy controls, a notable overlap of 161 differential metabolites and 3 enriched Kyoto Encyclopedia of Genes and Genomes pathways was observed in the HCC12 (comprising patients with stage I and II HCC) and HCC34 groups (comprising patients with stage III and IV HCC).

conclusionOur results suggest that the metabolome of fecal samples and the composition of intestinal bacteria hold promise as potential biomarkers for HCC diagnosis.

Indexed as

BacteriaBiomarkers, TumorCarcinoma, HepatocellularFecesGastrointestinal MicrobiomeLiver NeoplasmsMetabolomeAdultAgedCase-Control StudiesFemaleHigh-Throughput Nucleotide SequencingHumansMaleMetabolomicsMiddle AgedBiomarkers, TumorRNA, Ribosomal, 16SCorrelation analysisFecal metabolomicsHepatocellular carcinomaIntestinal bacteriaNon-targeted liquid chromatography-mass spectrometry

Identifiers

PMID40309232
PMCPMC12038548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.